Results

1–10 of 35 results for nAMD

Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update
Dante Joseph Pieramici, MD
Annual Meeting Talks
2022
Characteristics and Outcomes of nAMD Patients Managed in US Routine Clinical Practice: Analysis of the IRIS Registry Database
Anita Barikian, MD
Annual Meeting Talks
2022
End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2022
Demographic Variations in Response to Anti-VEGF in Treatment of Neovascular Wet Age-Related Macular Degeneration (nAMD) Patients: IRIS Registry Analysis
On Demand Cases, Courses, and Papers
2022
Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials
Dilsher S. Dhoot, MD
On Demand Cases, Courses, and Papers
2021
Impact of Duration of Exposure to Residual Intraretinal Fluid on Visual Function Outcomes in Neovascular Age-Related Macular Degeneration (nAMD)
Nathan C. Steinle, MD
On Demand Cases, Courses, and Papers
2021
Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2021
Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2021
Treatment Patterns and Visual and Health Function in Neovascular Age-Related Macular Degeneration (nAMD): Medicare Current Beneficiary Survey Analysis
Ferhina S Ali, MD, MPH
Annual Meeting Talks
2021